Peter Reinemer
Amministratore Delegato presso Opterion Health AG
Provenienza dei contatti di primo grado di Peter Reinemer
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Opterion Health AG
Opterion Health AG Medical/Nursing ServicesHealth Services Opterion Health AG is a Swiss company that focuses on bringing innovation to dialysis care and fostering home dialysis to improve the quality of life for patients suffering from end-stage renal disease (ESRD). Opterion Health is based in Muttenz, CH. The private company aims to increase the survival rates of people with ESRD and reduce healthcare costs. The company was founded in 2012 by Guido Grentzmann, and the CEO is Bjorn Englund.
6
| Holding Company | Medical/Nursing Services | 6 |
Max-Planck-Institute for Molecular Genetics
3
| College/University | Other Consumer Services | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Peter Reinemer tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Pharmaceuticals: Major | Director/Board Member | |
BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Bayer Pharmaceuticals Corp. | Chief Tech/Sci/R&D Officer | ||
NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
SARTORIUS AG | Pharmaceuticals: Major | Director/Board Member | |
Affidea Group BV
Affidea Group BV Medical/Nursing ServicesHealth Services Affidea Group BV provides diagnostic and renal care services. It is a medical service provider that offers diagnostic investigations, renal care, clinical laboratories, cancer treatment, and teleradiology services. The firm also operates centers for dialysis, diagnostic, and cancer treatment purposes. The company was founded in 1991 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Corporate Officer/Principal | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Karolinska Institutet | College/University | Corporate Officer/Principal | |
AS LATVIJAS GAZE | Gas Distributors | Director/Board Member | |
Kyowa Kirin International Plc
Kyowa Kirin International Plc Pharmaceuticals: MajorHealth Technology Kyowa Kirin International Plc is a specialty pharmaceutical company, which engages in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major markets. It offers Sancuso, a prescription medicine used to prevent nausea and vomiting in people receiving some types of chemotherapy treatment and Abstral, a medicine used in the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. The company was founded in 1995 and is headquartered in Galashiels, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
University of Uppsala | College/University | Graduate Degree | |
HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Chairman | |
University of Lund | College/University | Doctorate Degree | |
University of Surrey | College/University | Doctorate Degree | |
Bernhard-Nocht-Institut für Tropenmedizin
Bernhard-Nocht-Institut für Tropenmedizin Hospital/Nursing ManagementHealth Services The Bernhard-Nocht-Institut für Tropenmedizin is a research institute based in Hamburg, Germany. The institute focuses on tropical medicine and aims to minimize the risk of dangerous pathogens and toxins for everyone. The German company works with partner institutions in various countries to train laboratory staff and conduct research on diseases, diagnostics, and capacity strengthening. The institute also offers training courses, laboratory diagnostics, and information on travel and clinical research. | Hospital/Nursing Management | Corporate Officer/Principal | |
VERONA PHARMA PLC | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
S*BIO Pte Ltd.
S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Chief Executive Officer | |
AFFiRiS AG
AFFiRiS AG Medical/Nursing ServicesHealth Services AFFiRiS AG develops and produces vaccines for therapeutic treatment of chronic diseases. It provides research services and develops vaccines based on peptide antigens applied in the fields of biochemistry, molecular and cell biology, immunology and veterinary medicine. AFFiRiS was founded by Walter Schmidt and Frank Mattner in November 2003 and is headquartered in Vienna, Austria. | Medical/Nursing Services | Founder Chief Tech/Sci/R&D Officer | |
Vifor Pharma Management AG
Vifor Pharma Management AG Pharmaceuticals: MajorHealth Technology Vifor Pharma Management AG develops and manufactures pharmaceuticals products for the treatment of iron deficiency. It also offers a diversified portfolio of prescription medicines as well as over-the-counter products. The company operates in the following key business areas: iron deficiency with and without anemia, kidney disease, infectious diseases/OTX products and consumer healthcare, with a focus on non-prescription products. Vifor Pharma Management was founded by Caspar Friedrich Hausmann in 1872 and is headquartered in Glattbrugg, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
OM Pharma SA
OM Pharma SA Pharmaceuticals: MajorHealth Technology OM Pharma SA engages in manufacture of pharmaceutical products. Its portfolio includes products for respiratory tract infections, lower urinary tract infections, chronic venous insufficiency, microangiopathies, hemorrhoids, and menometrorrhagia. The company was founded by Jean-Rene Ricard in 1937 and is headquartered in Meyrin, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
Interpharma Investments Ltd.
Interpharma Investments Ltd. Pharmaceuticals: MajorHealth Technology Interpharma Investments Ltd. operates as a holding company with interest in the distribution and manufacturing of pharmaceutical products. It provides product development, planning and procurement, and commercial manufacturing services. It also offers marketing services and support solutions to the pharmaceutical companies. The company is headquartered in Hong Kong. | Pharmaceuticals: Major | Director/Board Member | |
Pfizer GmbH | Corporate Officer/Principal | ||
Galenica AB
Galenica AB Pharmaceuticals: MajorHealth Technology Galenica AB develops and manufactures pharmaceutical drugs. It offers service to partners for the development of oral, dermal, nasal, rectal, pulmonary and parenteral formulations of small molecules to peptides/proteins and biologics. The company was founded in 1999 and is headquartered in Malmo, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
SYNLAB International GmbH
SYNLAB International GmbH Medical/Nursing ServicesHealth Services SYNLAB International GmbH offers medical laboratory services for practicing doctors, clinics and the pharmaceutical industry. It offers medical instruments, transfusion medicines, cytology, pathology, human genetics, and general hygiene services. The company was founded by Bartl Wimmer in 1998 and is headquartered in Munich, Germany. | Medical/Nursing Services | Chairman | |
BZ Bank AG (Investment Management) | Investment Managers | Chief Executive Officer | |
Soho Flordis International Pty Ltd.
Soho Flordis International Pty Ltd. Pharmaceuticals: OtherHealth Technology Soho Flordis International Pty Ltd. manufactures natural medicine products. Its brands include flordis, ProThera, COMPLEMENTARY, ginsana and KLAIRE LABS. Its products include ginsana, keenmind, nuvexa and gincosan. The company was founded in 2010 and is headquartered in St. Leonards, Australia. | Pharmaceuticals: Other | Director/Board Member | |
iolite Capital Management AG
iolite Capital Management AG Investment ManagersFinance iolite Capital Management AG is an investment firm that was founded in 2008. The company is based in Zug, Switzerland. The Swiss company invests in mostly public companies with significant unrecognized value. The company applies an opportunistic, research-driven process that combines the best elements of private equity and public market investing. The company was founded in 2008 by Robert Leitz. Robert Leitz has been the CEO since 2008. | Investment Managers | Chief Executive Officer | |
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Miscellaneous Commercial Services | Chairman | |
SYNLAB AG | Medical/Nursing Services | Chairman | |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts. | Pharmaceuticals: Major | Founder |
Statistiche
Distribuzione geografica
Germania | 12 |
Regno Unito | 10 |
Svizzera | 7 |
Svezia | 5 |
Stati Uniti | 4 |
Settori
Health Technology | 25 |
Health Services | 6 |
Consumer Services | 5 |
Finance | 4 |
Utilities | 3 |
Posizioni
Director/Board Member | 19 |
Corporate Officer/Principal | 10 |
Chief Executive Officer | 9 |
Chairman | 8 |
Doctorate Degree | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Peter Reinemer
- Connessioni Società